References
- PfallerMADiekemaDJEpidemiology of invasive candidiasis: a persistent public health problemClin Microbiol Rev200720113316317223626
- HazenKCNew and emerging yeast pathogensClin Microbiol Rev1995844624788665465
- NobileCJJohnsonADCandida albicans biofilms and human diseaseAnnu Rev Microbiol201569719226488273
- CalderoneRAFonziWAVirulence factors of Candida albicansTrends Microbiol20019732733511435107
- WeigMGrossUMühlschlegelFClinical aspects and pathogenesis of Candida infectionTrends Microbiol199861246847010036723
- MoudgalVSobelJAntifungals to treat Candida albicansExpert Opin Pharmacother201011122037204820536294
- SheehanDJHitchcockCASibleyCMCurrent and emerging azole antifungal agentsClin Microbiol Rev199912140799880474
- ReVLCarbonariDMLewisJDOral azole antifungal medications and risk of acute liver injury, overall and by chronic liver disease statusAm J Med2016129328329126597673
- LevineMTChandrasekarPHAdverse effects of voriconazole: over a decade of useClin Transplant201630111377138627581783
- RamageGSavilleSPWickesBLLopez-RibotJLInhibition of Candida albicans biofilm formation by farnesol, a quorum-sensing moleculeAppl Environ Microbiol200268115459546312406738
- BaillieGSDouglasLJMatrix polymers of Candida biofilms and their possible role in biofilm resistance to antifungal agentsJ Antimicrob Chemother200046339740310980166
- DouglasLJCandida biofilms and their role in infectionTrends Microbiol2003111303612526852
- DonlanRMCostertonJWBiofilms: survival mechanisms of clinically relevant microorganismsClin Microbiol Rev200215216719311932229
- RamageGMowatEJonesBWilliamsCLopez-RibotJOur current understanding of fungal biofilmsCrit Rev Microbiol200935434035519863383
- TaylorEWebsterTJReducing infections through nanotechnology and nanoparticlesInt J Nanomedicine201161463147321796248
- BakerCPradhanAPakstisLPochanDJShahSISynthesis and antibacterial properties of silver nanoparticlesJ Nanosci Nanotechnol20055224424915853142
- HindiKMDittoAJPanznerMJThe antimicrobial efficacy of sustained release silver-carbene complex-loaded L-tyrosine poly-phosphate nanoparticles: characterization, in vitro and in vivo studiesBiomaterials200930223771377919395021
- ShangguanMQiJLuYWuWComparison of the oral bioavailability of silymarin-loaded lipid nanoparticles with their artificial lipolysate counterparts: implications on the contribution of integral structureInt J Pharm20154891–219520225956049
- SütőBBerkoSKozmaGDevelopment of ibuprofen-loaded nanostructured lipid carrier-based gels: characterization and investigation of in vitro and in vivo penetration through the skinInt J Nanomedicine2016111201121227099487
- AlomraniAHShazlyGAAmaraAABadranMMItraconazole-hydroxypropyl-β-cyclodextrin loaded deformable liposomes: in vitro skin penetration studies and antifungal efficacy using Candida albicans as modelColloids Surf B Biointerfaces2014121748124937135
- ChryssanthouECuenca-EstrellaMComparison of the Antifungal Susceptibility Testing Subcommittee of the European Committee on Antibiotic Susceptibility Testing proposed standard and the E-test with the NCCLS broth microdilution method for voriconazole and caspofungin susceptibility testing of yeast speciesJ Clin Microbiol200240103841384412354895
- NobileCJMitchellAPRegulation of cell-surface genes and biofilm formation by the C. albicans transcription factor Bcr1pCurr Biol200515121150115515964282
- WinKYFengSSEffects of particle size and surface coating on cellular uptake of polymeric nanoparticles for oral delivery of anticancer drugsBiomaterials200526152713272215585275
- LuanJZhengFYangXYuAZhaiGNanostructured lipid carriers for oral delivery of baicalin: in vitro and in vivo evaluationColloids Surf A Physicochem Eng Asp2015466154159
- DasSNgWKKanaujiaPKimSTanRBFormulation design, preparation and physicochemical characterizations of solid lipid nanoparticles containing a hydrophobic drug: effects of process variablesColloids Surf B Biointerfaces201188148348921831615
- MishraPRal ShaalLMüllerRHKeckCMProduction and characterization of hesperetin nanosuspensions for dermal deliveryInt J Pharm20093711–218218919162147
- AljuffaliIAHuangCHFangJYNanomedical strategies for targeting skin microbiomesCurr Drug Metab201516425527126264194
- AndesDNettJOschelPAlbrechtRMarchilloKPitulaADevelopment and characterization of an in vivo central venous catheter Candida albicans biofilm modelInfect Immun200472106023603115385506
- SollDRCandida biofilms: is adhesion sexy?Curr Biol20081816R717R72018727911
- De SordiLMühlschlegelFAQuorum sensing and fungal-bacterial interactions in Candida albicans: a communicative network regulating microbial coexistence and virulenceFEMS Yeast Res20099799099919845041
- SudberyPGowNBermanJThe distinct morphogenic states of Candida albicansTrends Microbiol200412731732415223059
- BrandAGowNAMechanisms of hypha orientation of fungiCurr Opin Microbiol200912435035719546023
- BaillieGSDouglasLJRole of dimorphism in the development of Candida albicans biofilmsJ Med Microbiol199948767167910403418
- BoyceKJAndrianopoulosAFungal dimorphism: the switch from hyphae to yeast is a specialized morphogenetic adaptation allowing colonization of a hostFEMS Microbiol Rev201539679781126253139
- NobleSMGianettiBAWitchleyJNCandida albicans cell-type switching and functional plasticity in the mammalian hostNat Rev Microbiol20171529610827867199
- PhanQTMyersCLFuYAls3 is a Candida albicans invasin that binds to cadherins and induces endocytosis by host cellsPLoS Biol200753e6417311474
- NettJLincolnLMarchilloKPutative role of β-1,3 glucans in Candida albicans biofilm resistanceAntimicrob Agents Chemother200751251052017130296